All News
Filter News
Found 809,012 articles
-
Bacainn Therapeutics Announces IND Clearance for BT051 and Initiation of Phase 1 Clinical Trial, Bacainn’s First Clinical Candidate for the Treatment of Ulcerative Colitis
6/9/2020
Bacainn Therapeutics, Inc., a Company developing novel therapies to address uncontrolled inflammation, announced today FDA’s Clearance of the IND for BT051, and initiation of a Phase 1 Clinical Trial with patient dosing expected in the coming months.
-
Olaris CEO Elected to Personalized Medicine Coalition Board of Directors
6/9/2020
Dr. Elizabeth O’Day will lead personalized medicine investment and adoption efforts globally during three-year term.
-
Virginia Based AMPEL BioSolutions' Technology Predicts Severity of Illness in COVID19 Patients and Identifies Treatments
6/9/2020
AMPEL BioSolutions announces genomic analysis and findings that could improve treatment of COVID19 patients with approved drugs such as Embrel and Stelara. Published on bioRxiv as a preprint, the study reveals a gene-based test that will be able to determine those patients who may progress to severe illness with increased like
-
New Capability in Vault PromoMats to Speed Packaging Promotional Materials for FDA Submission
6/9/2020
Veeva Systems (NYSE: VEEV) today announced at Veeva Summit Online a new capability in Veeva Vault PromoMats to speed the digital submission of promotional materials for accelerated approval products.
-
XyloCor Therapeutics Names Alexander Gaidamaka, PhD, Senior Vice President of Technology, Manufacturing & Quality
6/9/2020
XyloCor Therapeutics, a private clinical‑stage biopharmaceutical company focused on the development of gene therapy for unmet needs in cardiovascular disease, strengthens its leadership team with the appointment of Alexander Gaidamaka, PhD, as Senior Vice President of Technology, Manufacturing & Quality. Dr. Gaidamaka brings a wealth of product development, regulatory and manufacturing experience across multiple technolo
-
Medtronic Announces Scientific Data Presentations at the American Diabetes Association 80th Scientific Sessions
6/9/2020
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced its participation at the American Diabetes Association 80th scientific sessions virtual meeting, June 12-16, 2020. Medtronic will be participating in this year’s ADA virtual sessions with 16 data presentations, a symposium, a product theater, and a virtual exhibit.
-
New Research Resource from Beyond Type 1 Aims to Bridge the Gap Between Science and Community
6/9/2020
Through the JDRF – Beyond Type 1 Alliance, Beyond Type 1 has partnered with JDRF — the world's leading nonprofit funder of Type 1 diabetes (T1D) research — to educate the T1D community and the general public about current scientific developments, including the path to a cure for the chronic autoimmune condition.
-
Jazz Pharmaceuticals Announces Pricing of Private Offering of $850 Million of 2.000% Exchangeable Senior Notes due 2026
6/9/2020
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals") today announced the pricing of $850 million aggregate principal amount of 2.000% exchangeable senior notes due 2026 in a private offering (the "offering") by Jazz Investments I Limited, its wholly-owned subsidiary (the "Issuer"), to qualified institutional buyers pursuant to Ru
-
Revolution Medicines Announces Dosing of First Patient in Phase 1b Combination Study of RMC-4630 and AMG 510
6/9/2020
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier cancer targets, today announced dosing of the first patient in a Phase 1b clinical trial evaluating the combination of RMC-4630, the company’s investigational SHP2 inhibitor, and AMG 510, Amgen’s investigational KRASG12C inhibitor.
-
Liminal Announces Voting Results of Its 2020 Annual And Special General Meeting Of Shareholders (AGM)
6/9/2020
Liminal BioSciences Inc. (Nasdaq & TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company today announced the voting results from its Annual General and Special Meeting of Shareholders ("AGM") held virtually on June 8, 2020.
-
IncellDx’s Next Gen HPV/Cervical Cancer Assay (HPV OncoTect 3Dx) Receives Clinical Approval from Costa Rican Ministry of Health
6/9/2020
IncellDx, Inc., a global leader in single-cell diagnostics, announces approval by the Costa Rican Ministry of Health of its Next Generation HPV/cervical cancer assay, OncoTect 3Dx. This novel assay is the only test to simultaneously detect and quantify 3 molecular markers of cervical cancer—overexpression of oncogenes (E6, E7 mRNA), proliferation, and aneuploidy
-
Precipio Adds Another HemeScreen™ CustomerNewly Created Reagent Rental Program Continues to Gain HemeScreen Adopters
6/9/2020
- Specialty diagnostics company Precipio, Inc. ( NASDAQ: PRPO ), announced that Cancer and Hematology Centers of Western Michigan (CHCWM) has adopted Precipio’s HemeScreen technology to launch molecular testing assay for hematologic malignancies such as myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN). As part of Precipio’s recently launched Reagent Rental program, CHCWM’s laboratory is in the process of validati
-
BioAssured And Massey Services Partner To Launch New Long-Lasting Disinfecting System
6/9/2020
The creators of the BioAssured™ Process and BioAssured Certification ™ have announced a strategic partnership with Orlando headquartered, Massey Services. Serving over 650,000
-
PatientPing Secures $60 Million in Series C Funding to Continue Expansion of National Electronic Notifications Network
6/9/2020
Company to Scale Capabilities and Reach as Need for Real-Time Notifications About Patients' Care Encounters Becomes Federally Mandated [09-June-2020] BOSTON , June 9, 2020 /PRNewswire/ -- PatientPing , the nation's leading care collaboration and e-notifications platform, today announced that it has raised $60 million in Series C funding to fuel expansion to new g
-
Preliminary Findings of T1D Exchange’s Population Health Surveillance Study of COVID-19 in Individuals with Type 1 Diabetes Published in Diabetes Care
6/9/2020
Preliminary Findings of T1D Exchange’s Population Health Surveillance Study of COVID-19 in Individuals with Type 1 Diabetes Published in Diabetes Care First U.S. based, multi-center study to examine patient characteristics and adverse outcomes to drive advances in quality improvement and care best practices BOSTON--( BUSINESS WIRE )-- T1D Exchange announced that preliminary results of its population health surveillance study, “ Type 1 Diabetes and
-
Chelation Partners' Lead COVID-19 Product Shows Promise for Sepsis
6/9/2020
New published report highlights DIBI in development for COVID-19 and other infectious diseases.
-
Forma Therapeutics Announces Phase I Clinical Data for Investigational Agent FT-4202 in Sickle Cell Disease to be Presented at the Virtual Edition of the 25th European Hematology Association Annual Congress
6/9/2020
Forma Therapeutics Announces Phase I Clinical Data for Investigational Agent FT-4202 in Sickle Cell Disease to be Presented at the Virtual Edition of the 25 th European Hematology Association Annual Congress Poster presentation to highlight the tolerability, pharmacokinetics and pharmacodynamics of FT-4202 in Phase I clinical trials of single and multiple ascending dose cohorts of healthy subjects, Phase I clinical trials of single dose of SCD patients
-
OpGen Releases Preliminary Data Demonstrating its Unyvero HPN Panel for Pneumonia Identifies Life-Threatening Bacterial Co-Infections in COVID-19 Patients in Just Five Hours
6/9/2020
Performance of the Unyvero HPN Panel for pneumonia proves to be strongly concordant (98.2%) compared to bacterial lower respiratory tract culture Collaboration with Karolinska Institutet highlights critical need for rapid diagnostic tests, as one in four COVID-19 patients in the ICU had a bacterial co-infection Providing results in hours instead of days provides clinicians with early organism differential, including resistance marker information, allowing earlier treatment decisions and s
-
SS&C to Present at the RBC Capital Markets Financial Technology Virtual Conference
6/9/2020
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC), a global provider of software and software-enabled services for the financial services and healthcare industries, today announced that Rahul Kanwar, President and Chief Operating Officer, will present at the RBC Capital Markets Financial Technology Virtual Conference
-
C2i Genomics Raises $12 Million in Series A Funding
6/9/2020
C2i Genomics (“C2i”), a company dedicated to improving cancer patient lives and outcomes with a breakthrough tumor pattern recognition approach for liquid biopsy, today announced that it has raised $12 million in its Series A financing. The financing was led by Casdin Capital and joined by additional new investors including NFX Capital, The Mark Foundation for Cancer Research and other investors. Proceeds from the financing will